BlackRock, Inc. 13D and 13G filings for Viking Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-04 3:45 pm Purchase |
2024-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
BlackRock Inc. BLK |
5,872,642 5.300% |
408,663 (+7.48%) |
Filing |
| 2024-08-07 4:10 pm Sale |
2024-07-31 | 13G | Viking Therapeutics, Inc. VKTX |
BlackRock Inc. BLK |
5,463,979 4.900% |
-2,141,888 (-28.16%) |
Filing |
| 2024-01-26 11:49 am Purchase |
2023-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
BlackRock Inc. BLK |
7,605,867 7.600% |
6,178,646 (+432.91%) |
Filing |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Viking Therapeutics, Inc. VKTX |
BlackRock Inc. BLK |
1,427,221 1.800% |
-3,692,269 (-72.12%) |
Filing |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
BlackRock Inc. BLK |
5,119,490 6.500% |
-196,847 (-3.70%) |
Filing |
| 2021-02-01 08:30 am Purchase |
2020-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
BlackRock Inc. BLK |
5,316,337 7.300% |
609,076 (+12.94%) |
Filing |